Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 20/20 | 0.55 |
| ▸ | GIPR | P48546 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14039372 | 0.93 | GCGR (0.52) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL2667111 | 0.91 | GCGR (0.53) | GCGRGIPR | |
| SCHEMBL2667036 | 0.90 | GCGR (0.55) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL14039358 | 0.82 | GCGR (0.53) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL12789491 | 0.82 | GCGR (0.53) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL14039359 | 0.81 | GCGR (0.58) | GCGR | |
| SCHEMBL2667119 | 0.79 | GCGR (0.57) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL9071215 | 0.79 | GCGR (0.61) | GCGR | |
| SCHEMBL14039406 | 0.79 | FFAR1 (0.52) | GCGRGIPRCYP3A4CYP2C8CYP2C9 | |
| SCHEMBL14039371 | 0.79 | GCGR (0.54) | GCGRGIPRCYP3A4CYP2C8CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |